Induction of remission in biologic-naive, severe psoriasis and PsA with dual anti-cytokine combination.
作者信息
Haberman Rebecca H, Castillo Rochelle, Scher Jose U
机构信息
Department of Medicine, Division of Rheumatology, New York University School of Medicine and NYU Langone Orthopedic Hospital, New York, NY, USA.
出版信息
Rheumatology (Oxford). 2021 Jul 1;60(7):e225-e226. doi: 10.1093/rheumatology/keaa880.
Abstract
摘要
相似文献
1
Induction of remission in biologic-naive, severe psoriasis and PsA with dual anti-cytokine combination.使用双抗细胞因子联合疗法诱导初治的重度银屑病和银屑病关节炎缓解。
Rheumatology (Oxford). 2021 Jul 1;60(7):e225-e226. doi: 10.1093/rheumatology/keaa880.
2
Serum interleukin-6 levels in response to biologic treatment in patients with psoriasis.银屑病患者接受生物治疗后血清白细胞介素-6水平
Mod Rheumatol. 2017 Jan;27(1):137-141. doi: 10.3109/14397595.2016.1174328. Epub 2016 May 19.
3
Worsening of Psoriatic Arthritis After Ustekinumab Treatment.使用司库奇尤单抗治疗后银屑病关节炎病情恶化。
Am J Ther. 2018 May/Jun;25(3):e381-e382. doi: 10.1097/MJT.0000000000000546.
4
Paradoxical onset of psoriatic arthritis during treatment with biologic agents for plaque psoriasis: a combined dermatology and rheumatology clinical study.斑块状银屑病患者在使用生物制剂治疗期间出现银屑病关节炎的反常发作：一项皮肤科与风湿病学联合临床研究
Clin Exp Rheumatol. 2017 Jan-Feb;35(1):137-140. Epub 2016 Sep 8.
5
Successful ustekinumab treatment of noninfectious uveitis and concomitant severe psoriatic arthritis and plaque psoriasis.成功使用乌司奴单抗治疗非感染性葡萄膜炎，并伴有严重的银屑病关节炎和斑块型银屑病。
Dermatol Ther. 2017 Sep;30(5). doi: 10.1111/dth.12527. Epub 2017 Aug 18.
6
Psoriasis Area and Severity Index response in moderate-severe psoriatic patients switched to adalimumab: results from the OPPSA study.中重度银屑病患者换用阿达木单抗后的银屑病面积和严重程度指数应答：OPPSA 研究结果。
J Eur Acad Dermatol Venereol. 2018 Oct;32(10):1737-1744. doi: 10.1111/jdv.15077. Epub 2018 Jun 1.
7
Biological treatments for paediatric psoriasis : a retrospective observational study on biological drug survival in daily practice in childhood psoriasis.儿童银屑病的生物治疗：一项回顾性观察研究，评估生物药物在儿童银屑病日常治疗中的生存情况。
J Eur Acad Dermatol Venereol. 2019 Oct;33(10):1984-1992. doi: 10.1111/jdv.15579. Epub 2019 Apr 15.
8
Minimal disease activity in patients with psoriatic arthritis treated with ustekinumab: results from a 24-week real-world study.使用乌司奴单抗治疗的银屑病关节炎患者的最小疾病活动度：一项为期24周的真实世界研究结果
Clin Rheumatol. 2017 Jul;36(7):1589-1593. doi: 10.1007/s10067-017-3700-z. Epub 2017 May 31.
9
Severe dilated cardiomyopathy induced by adalimumab and ustekinumab.阿达木单抗和优特克单抗诱发的严重扩张型心肌病。
J Clin Rheumatol. 2015 Apr;21(3):171-3. doi: 10.1097/RHU.0000000000000237.
10
Comorbidity as a predictor for drug survival of biologic therapy in patients with psoriasis.共病作为银屑病患者生物治疗药物生存期的预测因素。
Int J Dermatol. 2016 Mar;55(3):296-302. doi: 10.1111/ijd.12879. Epub 2015 Oct 15.
引用本文的文献
1
The use of combination advanced therapies in psoriatic arthritis: results from a UK multi-centre audit.联合使用先进疗法治疗银屑病关节炎：英国多中心审计结果
Rheumatology (Oxford). 2025 May 1;64(5):3173-3176. doi: 10.1093/rheumatology/keaf037.
2
Difficult-to-treat psoriatic arthritis (D2T PsA): a scoping literature review informing a GRAPPA research project.难治性银屑病关节炎（D2T PsA）：一项文献综述，为 GRAPPA 研究项目提供信息。
RMD Open. 2024 Jan 8;10(1):e003809. doi: 10.1136/rmdopen-2023-003809.
3
Dual targeted therapy in patients with psoriatic arthritis and spondyloarthritis: a real-world multicenter experience from Spain.双靶向治疗银屑病关节炎和脊柱关节炎患者：来自西班牙的真实世界多中心经验。
Front Immunol. 2023 Oct 23;14:1283251. doi: 10.3389/fimmu.2023.1283251. eCollection 2023.
4
Dual Biologic Therapy in Patients with Rheumatoid Arthritis and Psoriatic Arthritis.类风湿关节炎和银屑病关节炎患者的双重生物制剂治疗
Rambam Maimonides Med J. 2023 Apr 30;14(2):e0007. doi: 10.5041/RMMJ.10494.
5
Efficacy of guselkumab, a selective IL-23 inhibitor, in Preventing Arthritis in a Multicentre Psoriasis At-Risk cohort (PAMPA): protocol of a randomised, double-blind, placebo controlled multicentre trial.选择性白细胞介素-23抑制剂古塞库单抗在预防多中心银屑病高危队列（PAMPA）关节炎中的疗效：一项随机、双盲、安慰剂对照多中心试验方案
BMJ Open. 2022 Dec 23;12(12):e063650. doi: 10.1136/bmjopen-2022-063650.
6
Psoriatic arthritis.银屑病关节炎。
Nat Rev Dis Primers. 2021 Aug 12;7(1):59. doi: 10.1038/s41572-021-00293-y.
本文引用的文献
1
Comparison between adalimumab introduction and methotrexate dose escalation in patients with inadequately controlled psoriatic arthritis (CONTROL): a randomised, open-label, two-part, phase 4 study.阿达木单抗引入与甲氨蝶呤剂量递增治疗中重度银屑病关节炎疗效对比研究（CONTROL）：一项随机、开放标签、两部分的4期研究。
Lancet Rheumatol. 2022 Apr;4(4):e262-e273. doi: 10.1016/S2665-9913(22)00008-X. Epub 2022 Feb 25.
2
Strategies to Improve Outcomes in Psoriatic Arthritis.改善银屑病关节炎结局的策略。
Curr Rheumatol Rep. 2019 Dec 7;21(12):72. doi: 10.1007/s11926-019-0876-z.
3
Dual biologic therapy for recalcitrant psoriasis and psoriatic arthritis.用于顽固性银屑病和银屑病关节炎的双重生物疗法。
JAAD Case Rep. 2019 Oct 10;5(10):928-930. doi: 10.1016/j.jdcr.2019.08.015. eCollection 2019 Oct.
4
Etanercept and Methotrexate as Monotherapy or in Combination for Psoriatic Arthritis: Primary Results From a Randomized, Controlled Phase III Trial.依那西普和甲氨蝶呤单药治疗或联合治疗银屑病关节炎：一项随机对照 III 期临床试验的主要结果。
Arthritis Rheumatol. 2019 Jul;71(7):1112-1124. doi: 10.1002/art.40851. Epub 2019 May 28.
5
Phase II Study of ABT-122, a Tumor Necrosis Factor- and Interleukin-17A-Targeted Dual Variable Domain Immunoglobulin, in Patients With Psoriatic Arthritis With an Inadequate Response to Methotrexate.ABT-122（一种针对肿瘤坏死因子和白细胞介素-17A 的双可变域免疫球蛋白）治疗甲氨蝶呤应答不足的银屑病关节炎的 II 期研究。
Arthritis Rheumatol. 2018 Nov;70(11):1778-1789. doi: 10.1002/art.40579.
6
Prevalence of rheumatologist-diagnosed psoriatic arthritis in patients with psoriasis in European/North American dermatology clinics.在欧洲/北美皮肤科诊所中，银屑病患者被风湿病学家诊断为银屑病关节炎的患病率。
J Am Acad Dermatol. 2013 Nov;69(5):729-735. doi: 10.1016/j.jaad.2013.07.023. Epub 2013 Aug 24.
7
Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial.与单药治疗相比，依那西普与甲氨蝶呤联合治疗类风湿关节炎患者的疗效：双盲随机对照试验
Lancet. 2004 Feb 28;363(9410):675-81. doi: 10.1016/S0140-6736(04)15640-7.
Zotero 插件